Home › Research › Disparities
Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence
Gleason CE, Zuelsdorff M, Gooding DC, Kind AJH, Johnson AL, James TT, Lambrou NH, Wyman MF et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2021-12-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Black Americans are disproportionately affected by dementia. To expand our understanding of mechanisms of this disparity, we look to Alzheimer's disease (AD) biomarkers. In this review, we summarize current data, comparing the few studies presenting these findings. Further, we contextualize the data using two influential frameworks: the National Institute on Aging-Alzheimer's Association (NIA-AA) Research Framework and NIA's Health Disparities Research Framework. The NIA-AA Research Framework provides a biological definition of AD that can be measured in vivo. However, current cut-points for determining pathological versus non-pathological status were developed using predominantly White cohorts-a serious limitation. The NIA's Health Disparities Research Framework is used to contextualize findings from studies identifying racial differences in biomarker levels, because studying biomakers in isolation cannot explain or reduce inequities. We offer recommendations to expand study beyond initial reports of racial differences. Specifically, life course experiences associated with racialization and commonly used study enrollment practices may better account for observations than exclusively biological explanations.
What this study adds
Evidence grade: Low
This is a narrative review. This review notes that current cut-points for defining Alzheimer's disease pathology were developed using predominantly White cohorts, which is a serious limitation for interpreting biomarker data in Black Americans. It recommends expanding studies beyond initial reports of racial differences and does not test a treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gleason, C. E., Zuelsdorff, M., Gooding, D. C., Kind, A. J. H., Johnson, A. L., James, T. T., et al. (2022). Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.12511
Vancouver
Gleason CE, Zuelsdorff M, Gooding DC, Kind AJH, Johnson AL, James TT, et al. Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022. doi:10.1002/alz.12511. PMID: 34870885.
BibTeX
@article{gleason2022-34870885,
author = {Gleason, C. E. and Zuelsdorff, M. and Gooding, D. C. and Kind, A. J. H. and Johnson, A. L. and James, T. T. and Lambrou, N. H. and Wyman, M. F. and others},
title = {{Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2022},
doi = {10.1002/alz.12511},
pmid = {34870885},
url = {https://doi.org/10.1002/alz.12511}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In this review, we summarize current data, comparing the few studies presenting these findings.
- However, current cut-points for determining pathological versus non-pathological status were developed using predominantly White cohorts-a serious limitation.
- Specifically, life course experiences associated with racialization and commonly used study enrollment practices may better account for observations than exclusively biological explanations.
Why it matters
This review notes that current cut-points for defining Alzheimer's disease pathology were developed using predominantly White cohorts, which is a serious limitation for interpreting biomarker data in Black Americans. It recommends expanding studies beyond initial reports of racial differences and does not test a treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Evidence strengthLow
How this study scored 55/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 103 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 17.2 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 4 / 6 | Cited 8.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 9 other studies in this library |
| Still being cited | 3 / 4 | Cited 73 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Henrik Zetterberg: h-index 196 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34870885) |
| Free to read | 2 / 2 | Free to read |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 32.
Later studies that cite this one
9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Disparities from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.